Clinical Trials of Texas, A Flourish Research Site

Background

Overview

Clinical Trials of Texas (CTT), now operating as Flourish Research, is a prominent clinical research organization based in San Antonio, Texas. Established in 2001 by Kay Scroggins, RN, the organization has over two decades of experience in conducting clinical trials across various therapeutic areas. CTT's mission is to advance medical research by providing high-quality clinical trial services, while its vision is to enhance patient health and wellness through innovative clinical research. The organization is recognized as one of the largest and most capable research sites in the United States.

Mission and Vision

• Mission: To advance medical research by providing high-quality clinical trial services.

• Vision: To enhance patient health and wellness through innovative clinical research.

Primary Area of Focus

CTT specializes in conducting clinical trials across multiple therapeutic areas, including cardiovascular/metabolic disorders, neuroscience, and infectious diseases. The organization is dedicated to advancing medical research by providing high-quality clinical trial services.

Industry Significance

CTT has played a significant role in the clinical research industry by conducting over 1,000 trials across more than 15 therapeutic areas and over 50 indications. The organization is recognized for its high-quality clinical trial services and has been instrumental in advancing medical research.

Key Strategic Focus

Core Objectives

• To conduct high-quality clinical trials across various therapeutic areas.

• To provide exceptional clinical experiences for patients.

• To advance medical research by facilitating the development of innovative treatments.

Specific Areas of Specialization

• Cardiovascular/Metabolic Disorders

• Neuroscience

• Infectious Diseases

Key Technologies Utilized

• State-of-the-art diagnostic equipment, including FibroScan, bladder scan, ECG, and cardiac monitoring.

• Temperature-controlled storage facilities for drug and vaccine storage.

• Advanced imaging and monitoring technologies.

Primary Markets or Conditions Targeted

• Cardiovascular diseases

• Metabolic disorders

• Neurological conditions

• Infectious diseases

Financials and Funding

Funding History

In August 2021, CTT was recapitalized by NMS Capital, leading to the formation of Flourish Research. This strategic move enabled the organization to expand its capabilities and service offerings.

Total Funds Raised

Specific details regarding the total funds raised by CTT are not publicly disclosed.

Notable Investors

• NMS Capital

Intended Utilization of Capital

The capital raised has been utilized to expand Flourish Research's network, enhance operational capabilities, and support the development of innovative treatments through clinical trials.

Pipeline Development

Key Pipeline Candidates

As a clinical research organization, CTT does not develop its own pipeline candidates but collaborates with pharmaceutical and biotechnology companies to conduct clinical trials for various investigational drugs and devices.

Stages of Clinical Trials or Product Development

• Phase I-IV clinical trials

Target Conditions

• Cardiovascular diseases

• Metabolic disorders

• Neurological conditions

• Infectious diseases

Relevant Timelines for Anticipated Milestones

Specific timelines for clinical trial milestones are determined by the sponsors and are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

CTT utilizes advanced diagnostic equipment and state-of-the-art facilities to conduct clinical trials. This includes specialized diagnostic equipment such as FibroScan, bladder scan, ECG, and cardiac monitoring, as well as temperature-controlled storage facilities for drug and vaccine storage.

Significant Scientific Methods

• Specialty injections

• Wearables/Insertables

• Specialty imaging

• Biopsies

• Insulin tolerance testing

• FibroScan

• PBMC

• Cardiac/Holter monitoring

• Food Effect/Meal Tolerance Testing

• Continuous glucose monitoring

• PK/PD sampling, processing & storage

• CSF sampling

• Infusions/PICC lines

• Slit lamp, fundoscopy & ophthalmological procedures

• Medical photography

Leadership Team

Key Executive Profiles

• Kay Scroggins, RN – Founder and CEO

• Over 20 years of experience in the clinical research industry.

• Recognized with the San Antonio Business Journal's "C-Suite Award for Small/Midsize Companies" in 2015.

• Honored as "2018 Woman Business Owner of the Year."

• Douglas Denham, DO, CPI – Chief Medical Director

• Board-certified physician with extensive experience in clinical research.

• Leisel Koerber, BBA, CCRC – Executive Vice President

• Over a decade of experience at CTT, leading operations and strategic initiatives.

Leadership Changes

Specific details regarding recent leadership changes are not publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The clinical research industry is experiencing significant growth, with a global market valued at approximately $21 billion. The demand for efficient patient recruitment and diverse patient populations is driving consolidation among clinical research sites.

Competitor Analysis

• Headlands Research

• Focuses on central nervous system (CNS) disorders and accessing diverse populations.

• Entered a multi-year partnership with Pfizer in May 2022 to increase diversity in clinical trials.

• Eximia Research

• Formed in October 2023 through a partnership between VSS Capital Partners and Dr. Ella Grach.

• Focuses on leveraging centralized services to support a network of sites and partner with leading pharma, biotech, and CROs.

Strategic Collaborations and Partnerships

CTT, as part of Flourish Research, has expanded its network through strategic acquisitions, including:

• Excel Medical Clinical Trials

• Acquired in October 2021, specializing in cardiology and related indications.

• Great Lakes Clinical Trials

• Acquired in January 2022, focusing on Alzheimer’s disease, psychiatry, vaccines, and nutrition-related research.

• Clinical Site Partners

• Acquired in January 2022, with a focus on respiratory, sleep, COVID-19, nephrology, and vaccine-related research.

Operational Insights

CTT's extensive experience and comprehensive facilities position it as a leading competitor in the clinical research industry. The organization's focus on high-quality clinical trials and patient-centric care provides a competitive advantage in attracting sponsors and participants.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Continue expanding the network through strategic acquisitions to enhance capabilities and geographic reach.

• Strengthen partnerships with pharmaceutical and biotechnology companies to conduct a diverse range of clinical trials.

• Enhance patient recruitment and retention strategies to support the efficient execution of clinical trials.

Future Business Directions

• Focus on emerging therapeutic areas to diversify the portfolio of clinical trials.

• Invest in advanced technologies to improve operational efficiency and data quality.

• Expand patient outreach programs to include underrepresented populations, enhancing the diversity of clinical trial participants.

Opportunities for Expansion

• Explore international markets to conduct global clinical trials.

• Develop specialized centers of excellence in specific therapeutic areas to attract targeted research opportunities.

Positioning for Future Objectives

CTT's established reputation, comprehensive facilities, and strategic partnerships position it well to achieve future objectives and maintain a leadership role in the clinical research